Most preclinical epilepsy research has been focused on the two main cannabinoids found in the plant, Δ9-tetrahydrocannabinol and cannabidiol (THC and CBD, respectively), and on synthetic agonists of cannabinoid receptors 1 and 2 (CB1R and CB2R, respectively). This evidence concerns the gene CNR1 and epilepsy.